Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNA, 7SL, cytoplasmic 638, pseudogene** (RN7SL638P) is a human pseudogene derived from the 7SL RNA sequence, an essential component of the signal recognition particle (SRP) involved in co-translational protein targeting in cells. 7SL RNA pseudogenes are non-functional, truncated copies of the original 7SL RNA gene, and are found in large numbers throughout the human genome as a consequence of retrotransposition. The vast majority of these pseudogenes, including RN7SL638P, are not expressed as functional RNAs and do not contribute to protein targeting or other canonical biological functions. They are generally considered genomic relics rather than active participants in any established disease pathway or therapeutic process[1][4][5][7]. **Key points**: - RN7SL638P is not a protein-coding gene nor a functional RNA gene; it is classified as a pseudogene—specifically, a non-coding, truncated, and typically non-expressed sequence related to 7SL RNA[4][7]. - 7SL RNA itself is central to the function of the SRP complex, but RN7SL638P does not encode this function and is regarded as a genomic byproduct rather than a direct functional or disease-associated gene[1][4][7]. - Therapeutically, RN7SL638P is not recognized as a target, biomarker, or drug interactor. - There is nothing unique or targetable about this specific pseudogene; its primary importance is for genome annotation or evolutionary studies. Based on available data, RN7SL638P is not a therapeutic target and is generally not relevant for clinical or pharmacological intervention[4][5][7]. The gene is catalogued for completeness in genomic databases but does not have biological/medical utility beyond that.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 638, pseudogene (RN7SL638P).